New ISTH recommendations regarding the use of DOACs for VTE prevention suggest rivaroxoban or apixaban are among appropriate anticoagulant options regardless of high BMI or weight. Previously, the 2016 guidance from the ISTH suggested not using DOACs in people with BMI >40 kg/m2 and weight >120 kg. The new recommendations, presented at ISTH 2021 and ...
ISTH 2021: New guidelines on DOAC use in obese patients
By Mardi Chapman
19 Jul 2021